Creative Planning Takes $299,000 Position in Castle Biosciences, Inc. (NASDAQ:CSTL)

Creative Planning bought a new position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 10,472 shares of the company’s stock, valued at approximately $299,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Castle Biosciences by 10.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,882 shares of the company’s stock worth $215,000 after purchasing an additional 952 shares during the last quarter. XTX Topco Ltd purchased a new stake in Castle Biosciences during the second quarter worth approximately $218,000. The Manufacturers Life Insurance Company lifted its stake in Castle Biosciences by 7.1% during the second quarter. The Manufacturers Life Insurance Company now owns 10,122 shares of the company’s stock worth $220,000 after purchasing an additional 675 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in Castle Biosciences by 89.3% during the first quarter. Allspring Global Investments Holdings LLC now owns 10,862 shares of the company’s stock worth $241,000 after purchasing an additional 5,123 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System purchased a new stake in Castle Biosciences during the first quarter worth approximately $249,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Insider Activity

In other news, insider Tobin W. Juvenal sold 3,507 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $35.56, for a total value of $124,708.92. Following the transaction, the insider now owns 54,178 shares of the company’s stock, valued at approximately $1,926,569.68. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, insider Tobin W. Juvenal sold 3,507 shares of the company’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $35.56, for a total transaction of $124,708.92. Following the transaction, the insider now owns 54,178 shares of the company’s stock, valued at $1,926,569.68. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Derek J. Maetzold sold 986 shares of the company’s stock in a transaction on Friday, October 4th. The stock was sold at an average price of $28.73, for a total value of $28,327.78. Following the transaction, the insider now directly owns 94,622 shares in the company, valued at $2,718,490.06. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 23,201 shares of company stock valued at $688,206. Company insiders own 7.20% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on CSTL shares. BTIG Research boosted their target price on Castle Biosciences from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Robert W. Baird boosted their price objective on Castle Biosciences from $37.00 to $39.00 and gave the company an “outperform” rating in a research note on Tuesday. Scotiabank boosted their price objective on Castle Biosciences from $37.00 to $44.00 and gave the company a “sector outperform” rating in a research note on Wednesday. KeyCorp boosted their price objective on Castle Biosciences from $28.00 to $36.00 and gave the company an “overweight” rating in a research note on Tuesday. Finally, Lake Street Capital boosted their price objective on Castle Biosciences from $34.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Castle Biosciences currently has an average rating of “Buy” and an average price target of $37.88.

Castle Biosciences Trading Down 0.1 %

NASDAQ:CSTL opened at $33.29 on Friday. The firm has a market cap of $919.14 million, a P/E ratio of 166.46 and a beta of 0.99. The company has a current ratio of 8.12, a quick ratio of 7.92 and a debt-to-equity ratio of 0.02. The stock’s 50 day simple moving average is $30.92 and its 200-day simple moving average is $25.87. Castle Biosciences, Inc. has a 12-month low of $16.20 and a 12-month high of $35.84.

Castle Biosciences (NASDAQ:CSTL) last released its earnings results on Monday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.14. The business had revenue of $85.78 million for the quarter, compared to analyst estimates of $78.55 million. Castle Biosciences had a return on equity of 1.50% and a net margin of 1.95%. During the same quarter in the previous year, the company posted ($0.26) earnings per share. Equities analysts anticipate that Castle Biosciences, Inc. will post -0.58 EPS for the current year.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.